Pharmacological, pharmacokinetic and clinical profile of meloxicam

Degner, FL

doi:10.1358/dot.1997.33.10.451138

Cited by 19 publications

(29 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In recent years, more COX-2 selective inhibitors have been developed with fewer side effects (Bombardier et al 2000, Feldman and McMahon 2000, Laine 2002, Gajraj 2003) and the same pain-reducing effects (Degner et al 1998, Schoenfeld 1999, Feldman and McMahon 2000. The effect on HO of this newer class of NSAIDs is described circumstantially: the effect of meloxicam is contrasting; some studies have shown the same effect (Legenstein et al 2003, van der Heide et al 2004, while another showed inferior results (Barthel et al 2002).…”

Section: Discussionmentioning

confidence: 99%

Similar effects of rofecoxib and indomethacin on the incidence of heterotopic ossification after hip arthroplasty

et al. 2007

View full text Add to dashboard Cite

Background Although indomethacin is effective in preventing heterotopic ossification (HO) after primary total hip arthroplasty, side effects are frequently observed. In the last decade a new class of drugs-the COX-2 selective nonsteroidal anti-inflammatory drugs-has been developed. To investigate the effect of these COX-2 selective NSAIDs on heterotopic ossification (HO) after primary total hip arthroplasty (THA), we conducted a randomized controlled trial using either indomethacin or rofecoxib for 7 days.Methods 186 patients received either indomethacin 3 times daily, or rofecoxib twice, and 1 placebo, daily for 7 days. HO was graded according to the 1-year postoperative radiographs according to the Brooker classification.Results 12 of the 186 patients included discontinued their medication before the end of the trial due to side effects. The remaining 174 patients were included in the analysis. In the indomethacin group (n = 89), 77 patients (87%) showed no HO, 9 showed HO of grade 1 and 3 showed HO of grade 2 according to the Brooker classification. In the rofecoxib group (n = 85) 73 patients (86%) showed no ossification, 9 showed grade 1, and 3 showed grade 2.Interpretation The prophylactic effect of rofecoxib for 7 days in preventing heteropic ossification after primary total hip arthroplasty is comparable to the effect of indomethacin given for 7 days. These results indicate that the development of HO follows a COX-2 pathway.

show abstract

Section: Discussionmentioning

confidence: 99%

Similar effects of rofecoxib and indomethacin on the incidence of heterotopic ossification after hip arthroplasty

et al. 2007

View full text Add to dashboard Cite

show abstract

“…A total of 20,084 patients were treated with meloxicam in early clinical efficacy and safety studies (Degner et al, 2001). These trials showed that meloxicam was as effective as diclofenac or piroxicam (Hosie et al, 1996(Hosie et al, , 1997Linden et al, 1996;Goei et al, 1997) and more effective than placebo (Lund et al, 1998) in patients diagnosed with OA.…”

Section: A Treatment Of Inflammatory Diseasesmentioning

confidence: 99%

Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition

2004

View full text Add to dashboard Cite

“…Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) with selectivity towards COX-2 compared with COX-1 [1]. It is almost completely absorbed following oral administration with an absolute bioavailability of 89%.…”

Section: Introductionmentioning

confidence: 99%

Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients

Meineke

Türck

2003

Brit J Clinical Pharma

View full text Add to dashboard Cite

Aim To perform a nonlinear mixed effect modelling (NONMEM) population pharmacokinetic analysis of meloxicam plasma concentrations in rheumatoid arthritis (RA) patients participating in three clinical trials, and to evaluate the effects of age, weight, gender and concomitant medications on meloxicam pharmacokinetics. Methods Meloxicam was administered to RA patients once daily for 3 weeks or 6 months at doses between 7.5 and 60 mg. Plasma samples were obtained at least 7 days after the first dose and meloxicam plasma concentrations were quantified by h.p.l.c.. Results NONMEM analysis was conducted on plasma samples derived from 586 patients. A one-compartmental model was found to describe the data adequately. For a typical subject in the population, a clearance of 0.377 l h -1 (95% confidence interval (CI) 0.0304-0.449) in males and 0.347 l h -1 (95% CI 0.274-0.419) in females was obtained. The volume of distribution was estimated to be 14.9 l. The findings were corroborated by subsequent analysis using WinBUGS. Analysis of covariates showed that age and gender both significantly ( P < 0.005) affected clearance. The effect of age was relatively small and a dose adjustment of <10% was deemed unnecessary. Differences between males and females were attributed to differences in weight. No clinically relevant drug-drug interactions were found, although sulphasalazine and glucocorticoids both significantly ( P < 0.005) affected meloxicam clearance ( + 19% and -12%, respectively). The mechanisms by which these agents affect meloxicam clearance remain to be elucidated. Conclusions The population pharmacokinetic meloxicam data from patients with RA gave similar results to those obtained from phase I trials. However, uncommon drug interactions may not be detected in phase I trials because of the small number of observations made.

show abstract

Pharmacological, pharmacokinetic and clinical profile of meloxicam

Cited by 19 publications

References 0 publications

Similar effects of rofecoxib and indomethacin on the incidence of heterotopic ossification after hip arthroplasty

Similar effects of rofecoxib and indomethacin on the incidence of heterotopic ossification after hip arthroplasty

Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition

Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients

Contact Info

Product

Resources

About